Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study
This study has been completed.
Sponsor:
Yonsei University
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
NCT00968136
First received: August 27, 2009
Last updated: NA
Last verified: August 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a randomized, controlled study to compare Short-term ketogenic diet with conventional long-term trial in refractory infantile spasms.
| Condition |
|---|
|
Infantile Spasms |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
Resource links provided by NLM:
Genetics Home Reference related topics:
pyridoxal 5'-phosphate-dependent epilepsy
X-linked infantile spasm syndrome
U.S. FDA Resources
Further study details as provided by Yonsei University:
Primary Outcome Measures:
- Primary outcome measures include seizure relapse and frequency after successful completion of the ketogenic diet. [ Time Frame: Finally, 35 patients could be followed up for more than 12 months after successful discontinuation of the diet and then primary outcome will be measured. ]
| Groups/Cohorts |
|---|
| a short-term trial of the ketogenic diet |
| long-term trial of the ketogenic diet. |
Eligibility| Ages Eligible for Study: | 1 Month to 5 Years |
| Genders Eligible for Study: | Both |
| Sampling Method: | Non-Probability Sample |
Study Population
refractory infantile spasms
Criteria
Inclusion Criteria:
- Patients, who have recalcitrant infantile spasms and undertake the ketogenic diet at Severance Hospital and Sanggye Paik Hospital from 2005 to 2008.
- Clinical and electroencephalography findings are compatible with infantile spasms
- Spasms are intractable to the initial combination of vigabatrin (150 mg/kg) and topiramate (10 mg/kg) and/or additional indicated anti-epileptic drugs including prednisolone (2 mg/kg for 2 weeks and an additional 2 weeks for tapering).
- Study entry requires magnetic resonance imaging to confirm the absence of a progressive cerebral lesion.
Exclusion Criteria:
- Patients who have a history of hyperlipidaemia and underlying metabolic diseases including acute intermittent porphyria, pyruvate carboxylase deficiency, and fatty acid oxidation defects.
- Patients who have a history of nephrolithiasis.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No Contacts or Locations Provided
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00968136 History of Changes |
| Other Study ID Numbers: | 4-2006-0020 |
| Study First Received: | August 27, 2009 |
| Last Updated: | August 27, 2009 |
| Health Authority: | Korea: Food and Drug Administration Korea: Ministry for Health and Welfare |
Keywords provided by Yonsei University:
|
refractory infantile spasms |
Additional relevant MeSH terms:
|
Spasms, Infantile Brain Diseases Central Nervous System Diseases |
Epilepsy Epilepsy, Generalized Nervous System Diseases |
ClinicalTrials.gov processed this record on March 03, 2015